Brokerages Set ICON Public Limited (NASDAQ:ICLR) Target Price at $215.33

Shares of ICON Public Limited (NASDAQ:ICLR - Get Free Report) have received an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $215.33.

ICLR has been the subject of a number of analyst reports. TD Cowen downgraded shares of ICON Public from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $254.00 to $157.00 in a research report on Monday, April 14th. The Goldman Sachs Group reduced their price target on shares of ICON Public from $180.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. JPMorgan Chase & Co. downgraded shares of ICON Public from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $265.00 to $150.00 in a research report on Tuesday, April 29th. William Blair restated an "outperform" rating on shares of ICON Public in a research report on Tuesday, January 14th. Finally, Citigroup reduced their price target on shares of ICON Public from $290.00 to $215.00 and set a "buy" rating for the company in a research report on Monday, April 7th.

Institutional Trading of ICON Public

Several institutional investors have recently added to or reduced their stakes in ICLR. GAMMA Investing LLC increased its holdings in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock valued at $91,000 after purchasing an additional 169 shares during the last quarter. Steph & Co. boosted its position in ICON Public by 3.7% in the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company's stock valued at $327,000 after buying an additional 55 shares during the period. Park Place Capital Corp boosted its position in ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock valued at $47,000 after buying an additional 166 shares during the period. Avior Wealth Management LLC boosted its position in ICON Public by 76.0% in the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company's stock valued at $187,000 after buying an additional 386 shares during the period. Finally, Tributary Capital Management LLC boosted its position in ICON Public by 116.1% in the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company's stock valued at $828,000 after buying an additional 2,122 shares during the period. Institutional investors and hedge funds own 95.61% of the company's stock.

ICON Public Stock Performance

NASDAQ ICLR traded up $5.39 on Wednesday, reaching $139.35. 143,827 shares of the company's stock traded hands, compared to its average volume of 1,005,767. The firm has a market cap of $11.25 billion, a price-to-earnings ratio of 14.59, a P/E/G ratio of 1.86 and a beta of 1.23. The stock has a 50 day moving average price of $159.93 and a 200-day moving average price of $189.97. ICON Public has a fifty-two week low of $133.28 and a fifty-two week high of $347.72. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, topping analysts' consensus estimates of $3.17 by $0.02. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.03 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The company's revenue was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.47 earnings per share. Equities research analysts predict that ICON Public will post 13.38 EPS for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.